HDAC2: Histone deacetylase 2
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who Is On It, and How Far Along
Every drug ChEMBL records acting on HDAC2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Vorinostat | Approved | Merck & Co. (MSD) | Small molecule | Inhibitor | Histone deacetylase 2 inhibitor | 28 | — |
| Mocetinostat | Phase 2 | Mirati Therapeutics Inc. | Small molecule | Inhibitor | Histone deacetylase 2 inhibitor | 2 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Neoplasm
- 0.57
- Primary cutaneous T-cell non-Hodgkin lymphoma
- 0.57
- Plasma cell myeloma
- 0.56
- Neurodegenerative disease
- 0.52
- T-cell non-Hodgkin lymphoma
- 0.52
- Peripheral T-cell lymphoma, not otherwise specified
- 0.52
- Mature T-cell and NK-cell non-Hodgkin lymphoma
- 0.51
- Breast cancer
- 0.40
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- HDAC2
- Related
- Histone deacetylase
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1937, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q92769, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets